This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BHQ880
Description: BHQ880 is a first-in-class, fully human, HuCAL IgG1, anti-Dickkopf-1 (DKK-1) neutralizing antibody.
DKK-1 is a soluble Wnt pathway antagonist expressed predominantly in bone in adults and is upregulated in myeloma patients with osteolytic lesions. The Wnt pathway is a major regulator of mesenchymal stem cell (MSC) differentiation into osteoblasts. It is also an important survival factor for active osteoblasts.
Deal Structure: In 2007, Novartis and MorphoSys AG formed a comprehensive, 10-year, $600 million strategic alliance for the discovery and development of biopharmaceuticals. Novartis and MorphoSys will jointly discover and optimize antibodies against a significant number of molecular targets in a wide range of diseases.
Based on a 10-year term, Novartis has committed to making total payments, including FTE support, technology transfer, and annual licensing fees of approximately USD 600 million to MorphoSys. Potential payments could exceed USD 1 billion when including milestones that are contingent upon successful clinical development and market approval of multiple products. MorphoSys may also participate in co-development and assume co-detailing responsibility for selected projects.
Partners: MorphoSys AG
Additional information available to subscribers only: